Mycophenolic acid in the treatment of psoriasis: long-term administration.

Mycophenolic acid in the treatment of psoriasis: long-term administration. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Mycophenolic acid in the treatment of psoriasis: long-term administration. Abstract Text:

Thirty five patients with psoriasis (plaque type 26, guttate 3, pustular 4, and erythrodermic 2) were treated with oral mycophenolic acid for a period ranging from 52 to 104 weeks. The average follow-up was 89 weeks, and the dose schedule ranged from 2,400 to 7,200 mg daily. Excellent response was noted in 20 patients, good in 13 patients, and poor in 2. The most common clinical side effects were in the gastrointestinal tract, namely, diarrhea, nausea, abdominal cramps, and soft stools. A high incidence of herpes simplex, herpes zoster, and a flu-like syndrome was noted. Laboratory abnormalities consisted of mild blood hemoglobin reduction, one case of leukopenia (3,9000 WBCs per cubic millimeter), two cases with thrombocytopenia and mild elevation of alkaline phosphatase. Mycophenolic acid appears as a promising drug for the treatment of severe psoriasis.

Mycophenolic acid in the treatment of psoriasis: long-term administration. Publishing Authors By Initials

For similar virus diseases research abstracts see: virus diseases research

PUBMED ID PMID:

MEDLINE DATE:

Mycophenolic acid in the treatment of psoriasis: long-term administration. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Archives of dermatology

VOLUME: 113

Page Numbers: 930-2

Journal Abbreviation: Arch Dermatol

ISSN: 0003-987X

DAY: 17

MONTH: Jul

YEAR: 1977

Mycophenolic acid in the treatment of psoriasis: long-term administration. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372433

Mycophenolic acid in the treatment of psoriasis: long-term administration. Keywords Mesh Terms:

KEYWORDS: Virus Diseases

MESH TERMS: complications

Chemical & Substance for Abstract: Mycophenolic acid in the treatment of psoriasis: long-term administration. Information

Substance Name: Mycophenolic Acid

Registry Number: 24280-93-1

Grant and Affiliation Information for Mycophenolic acid in the treatment of psoriasis: long-term administration.

AFFILIATION:

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Arch Dermatol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Mycophenolic acid in the treatment of psoriasis: long-term administration Related Publications

• A chimeric cysteine protease of Plasmodium berghei engineered to resemble the Plasmodium falciparum protease falcipain-2.
• A comparison of total hip and knee replacement in specialty and general hospitals.
• Adolescent girls' communication with "mothers" about topical microbicides.
• Adolescents' descriptions of the physical characteristics of microbicide surrogates and experiences of use.
• Aerosol probes of emphysema progression in dogs treated with all trans retinoic acid--an exploratory study.
• Altered allergen-induced eosinophil trafficking and physiological dysfunction in airways with preexisting virus-induced injury.
• An interpersonal continuity of care measure for Medicare Part B claims analyses.
• Carcinoid associated encephalitis successfully treated with tryptophan.
• Change of European editor.
• Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial.
• Comparison of HRP2- and pLDH-based rapid diagnostic tests for malaria with longitudinal follow-up in Kampala, Uganda.
• Comparison of the Traumatic Brain Injury (TBI) Model Systems national dataset to a population-based cohort of TBI hospitalizations.
• Dual use of Medicare and the Veterans Health Administration: are there adverse health outcomes?
• Exploring the association of dual use of the VHA and Medicare with mortality: separating the contributions of inpatient and outpatient services.
• Fisheries and aquaculture industries involvement to control product health and quality safety to satisfy consumer-driven objectives on retail markets in Europe.
• Guarding against vascular site infection: Arm yourself with the latest knowledge on equipment and technique to protect patients from catheter-related bloodstream infections.
• Homogeneously alloyed CdSxSe1-x nanocrystals: synthesis, characterization, and composition/size-dependent band gap.
• Information about cancer clinical trials: an analysis of Internet resources.
• Measurement of microbicide acceptability among U.S. adolescent girls.
• Oximetry-guided reoxygenation improves neurological outcome after experimental cardiac arrest.
• Perceptions of sexual assertiveness among adolescent girls: initiation, refusal, and use of protective behaviors.
• Physician-owned specialty hospitals and coronary revascularization utilization: too much of a good thing?
• Quantum dot probes for monitoring dynamic cellular response: reporters of T cell activation.
• Report of a hürthle cell neoplasm in a peripubertal girl.
• Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda.
• Role of calcium channel blockers in the future, in view of the INSIGHT Study.
• Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts.
• Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum.
• Universal polyethylene glycol linkers for attaching receptor ligands to quantum dots.
• When adolescent girls say, "I don't know".